scholarly journals Balancing Expectations for Success in Stem Cell-Based Clinical Trials for Parkinson’s Disease

2020 ◽  
Vol 27 (4) ◽  
pp. 519-522
Author(s):  
Olle Lindvall
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Clinical Trials ◽  
Stem Cell

scholarly journals Stem Derived Dopamine Neurons: Will They Replace DBS as the Leading Neurosurgical Treatment for Parkinson’s Disease?

2021 ◽  
pp. 1-9
Author(s):  
Roger A. Barker ◽  
Anders Björklund ◽  
Steven J. Frucht ◽  
Clive N. Svendsen
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Clinical Trials ◽  
Stem Cell ◽  
Dopamine Neurons ◽  
Positive Outcomes ◽  
Critical Pathway ◽  
The Future ◽  
Neurosurgical Treatment

The use of stem cell derived dopamine neurons for treating patients with Parkinson’s disease has now evolved to the first in human clinical trials. In this debate, we argue that assuming these trials give positive outcomes that this therapy will supercede DBS as the neurosurgical treatment of choice for PD patients in the future given it is a one-off therapy that repairs a critical pathway in the parkinsonian brain.

Stem cell deficiency in Parkinson's disease

2005 ◽  
Vol 32 (06) ◽  
Author(s):  
GU Höglinger ◽  
P Rizk ◽  
WH Oertel ◽  
EC Hisch
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Stem Cell

scholarly journals Erratum: Chen, Y.-R., et al. Improvement of Impaired Motor Functions by Human Dental Exfoliated Deciduous Teeth Stem Cell-Derived Factors in a Rat Model of Parkinson’s Disease. Int. J. Mol. Sci. 2020, 21, 3807

2021 ◽  
Vol 22 (3) ◽  
pp. 1154
Author(s):  
Yong-Ren Chen ◽  
Pei-Lun Lai ◽  
Yueh Chien ◽  
Po-Hui Lee ◽  
Ying-Hsiu Lai ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Stem Cell ◽  
Rat Model ◽  
Deciduous Teeth ◽  
Motor Functions

The authors regret to have made a mistake in publishing this paper [...]

scholarly journals Bringing Advanced Therapies for Parkinson’s Disease to the Clinic: The Scientist’s Perspective

2021 ◽  
pp. 1-6
Author(s):  
Mark Tomishima ◽  
Agnete Kirkeby
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Clinical Trials ◽  
Phase I Clinical Trials ◽  
Preclinical Models ◽  
Preclinical Development ◽  
Dopaminergic Medication ◽  
Gene Therapies ◽  
Advanced Therapies ◽  
New Phase

After many years of preclinical development, cell and gene therapies have advanced from research tools in the lab to clinical-grade products for patients, and today they constitute more than a quarter of all new Phase I clinical trials for Parkinson’s disease. Whereas efficacy has been convincingly proven for many of these products in preclinical models, the field is now entering a new phase where the functionality and safety of these products will need to stand the test in clinical trials. If successful, these new products can have the potential to provide patients with a one-time administered treatment which may alleviate them from daily symptomatic dopaminergic medication.

Sign in / Sign up

Export Citation Format

Share Document